EGFR and neoplasm: The addition of erlotinib or si-EGFR to the medium reduced the level of p-STAT3 (Fig. 7B and Supplementary Fig. 4C); therefore, we conclude that NNMT promotes tumor proliferation and metastasis through the EGFR-STAT3 pathway.